Meta-analysis shows CD133 predicts poor prognosis in liver cancer, indicating its clinicopathological significance.
Background: This meta-analysis was conducted to investigate whether CD133 could be used as a biomarker to predict prognosis in hepatocellular carcinoma patients. Methods: We systematically retrieved relevant studies from these databases as of February 2026. Odds ratios and their 95% confidence intervals were used to estimate the association between CD133 expression and clinicopathological features. The associations between CD133 and survival outcomes, including overall survival (OS), disease-free survival, and recurrence-free survival, were estimated by hazard ratios and 95% confidence intervals. Results: A total of 25 publications were included, involving 3278 patients. CD133 was highly expressed in liver cancer tissues ( P < .05). Also, CD133 expression was associated with tumor size, tumor node metastasis stage, and tumor differentiation ( P < .05). CD133-positive expression had shorter OS, disease-free survival, and recurrence-free survival than those with CD133-negative expression ( P < .05). Conclusion: This meta-analysis suggests that CD133 is a potential biomarker for predicting poor survival in Asian hepatocellular carcinoma patients, especially for OS.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: